Physician profile
Daniel J Press
NPI 1790984672
$9,547.83
in general payments reported to CMS, 2019-2025
16 companies · $527 in 2025
The $527 reported for 2025 was more than what 82% of Pediatrics (Optometrist) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $566 · 2021: $610 · 2022: $265 · 2023: $5,314 · 2024: $575 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,550 · Food and Beverage: $1,472 · Consulting Fee: $1,381 · Travel and Lodging: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,550.00 |
| Food and Beverage | $1,471.62 |
| Consulting Fee | $1,381.24 |
| Travel and Lodging | $1,013.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $4,881.40 | 2021-2024 | Acuvue |
| Visioneering Technologies, INC. | $2,018.92 | 2019-2020 | |
| Coopervision INC. | $1,131.71 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Lumenis Be INC | $358.55 | 2024-2025 | Optilight |
| Bausch & Lomb Americas INC. | $309.32 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $212.00 | 2019-2025 | Total30, Dailies Total1, Eysuvis |
| Novartis Pharmaceuticals Corporation | $199.53 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $95.45 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.13 | 2021 | |
| Sun Pharmaceutical Industries INC. | $76.22 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $65.09 | 2022 | |
| Biotissue Holdings INC. | $24.04 | 2024 | |
| Lkc Technologies, INC. | $23.76 | 2025 | |
| Oyster Point Pharma, INC. | $22.91 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.65 | 2025 | Xdemvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Press listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.